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Despite recent advances, the expression of heterologous proteins in Escherichia
coli for crystallization remains a nontrivial challenge. The present study
investigates the efﬁcacy of maltose-binding protein (MBP) fusion as a general
strategy for rescuing the expression of target proteins. From a group of
sequence-veriﬁed clones with undetectable levels of protein expression in an
E. coli T7 expression system, 95 clones representing 16 phylogenetically diverse
organisms were selected for recloning into a chimeric expression vector with an
N-terminal histidine-tagged MBP. PCR-ampliﬁed inserts were annealed into
an identical ligation-independent cloning region in an MBP-fusion vector and
were analyzed for expression and solubility by high-throughput nickel-afﬁnity
binding. This approach yielded detectable expression of 72% of the clones;
soluble expression was visible in 62%. However, the solubility of most proteins
was marginalto poor upon cleavage of the MBP tag.This study offerslarge-scale
evidence that MBP can improve the soluble expression of previously non-
expressing proteins from a variety of eukaryotic and prokaryotic organisms.
While the behavior of the cleaved proteins was disappointing, further
reﬁnements in MBP tagging may permit the more widespread use of MBP-
fusion proteins in crystallographic studies.
1. Introduction
The process of solving three-dimensional protein structures by X-ray
crystallography is a multi-stage effort with unique challenges at each
step. The initial challenge is expression of the protein in a sufﬁcient
quantity and with sufﬁcient purity to obtain diffraction-quality crys-
tals. Typically, recombinant proteins are expressed in Escherichia coli
with small afﬁnity tags such as hexahistidine (His tag) to allow efﬁ-
cient separation of the desired protein by afﬁnity chromatography
(Arnold, 1991). E. coli expression systems are a proven and cost-
effective method of producing large quantities of high-quality
recombinant proteins (Arnold, 1991; Gathmann et al., 2006; Mus-
Veteau, 2002). However, this approach is often insufﬁcient for soluble
expression of recombinant protein. The Structural Genomics Center
has estimated that up to 50% of all prokaryotic proteins are insoluble
when expressed in E. coli (Edwards et al., 2000). Failure to express
soluble eukaryotic proteins is even more common; for instance,
reports indicate that only 6–20% of human and Plasmodium proteins
are solubly expressed using standard expression methods (Stevens,
2000; Mehlin et al., 2006). Insoluble protein expression is thus a major
impediment to structural genomics efforts.
One strategy for increasing expression and solubility is fusing the
target protein to a large afﬁnity tag such as glutathione S-transferase
(GST),thioredoxin (TRX)or maltose-bindingprotein(MBP) (Smith,
2000; Sachdev & Chirgwin, 2000; LaVallie et al., 2000; Kapust &
Waugh, 1999). Of these, the most promising may be MBP. Although
unaltered MBP can be puriﬁed using a cross-linked amylose resin
afﬁnity matrix, addition of a His tag or GST improves the yield and
purity (Pryor & Leiting, 1997). His-tagged MBP-fusion constructs
therefore allow metal-afﬁnity puriﬁcation strategies combined with
the potential for increased solubility (di Guan et al., 1988).
Previous studies have provided preliminary evidence of the ability
of MBP to rescue the expression and solubility of proteins. In a
comparison of three macromolecule chimeric constructs, MBP wasfar more effective than GST or TRX in solubilizing six notoriously
insoluble proteins (Kapust & Waugh, 1999). In a study of 32 small
human proteins expressed in E. coli in tandem with MBP, researchers
observed increased solubility and expression in 19 out of 32 con-
structs compared with His-tag expression (Hammarstro ¨met al., 2002).
In an examination of membrane proteins from Mycobacterium
tuberculosis, the expression of 16 out of 22 proteins was rescued by
fusion to MBP and 13 of these 16 were soluble (Korepanova et al.,
2007). A larger study by Kataeva et al. (2005) observed increased
soluble expression levels in 60 out of 66 Clostridium thermocellum
and 38 out of 79 Shewanella oneidensis proteins when targets were
expressed fused to MBP in combination with decreased induction
temperatures, compared with the expression of GSTor NusA fusion
partners. To our knowledge, however, a large-scale study of the
effects of MBP on proteins from diverse eukaryotic and prokaryotic
organisms has yet to be reported.
The goal of this study was to examine fusion proteins on a scale
permitting a highly accurate assessment of the rescue rate of MBP.
We attempted MBP-mediated rescue of 95 His-tagged targets from
diverse sources. These targets had no soluble or total expression but
were sequence-validated, ensuring that the lack of expression was not
attributable to an incorrect target or an empty vector.
2. Methods
Targets for the SSGCID pipeline were selected for their predicted
essentiality, virulence factor and general potential as drug targets. For
cloning, targets were ampliﬁed from either puriﬁed genomic DNA or
cDNA using standardized primers containing sequences speciﬁc for
the cloning site followed by a sequence complementary (adjusted
to 331 K Tm) to the template gene: FWD primer 50-GGGTCCTG-
GTTCATG...-30 and REV primer 50-CTTGTTCGTGCTGTTTA-
TTA...-30 (Invitrogen). PCR conditions were optimized depending
on the G+C content of the template sequence. A typical reaction
mixture was as follows: 35.2 mld H 2O (Sigma, catalog No. W3513),
5 ml Expand High Fidelity Buffer (10 )w i t h1 5m M MgCl2 (Roche),
0.4 ml2 5m M dNTPs (Qiagen, catalog No. 201912), 0.4 ml Expand
High Fidelity Enzyme Mix (Roche, catalog No. 11732641001), 4 ml
(10 mM) FWD primer, 4 ml (10 mM) REV primer and 1 ml (10 ng) of
the respective template DNA. PCR amplicons were run on a 1%
agarose gel to verify the expected size of the ampliﬁed gene; the band
was then excised from the gel and extracted from the agarose using a
QiaQuick kit (Qiagen, catalog No. 28181). The puriﬁed PCR product
was cloned into expression vector AVA0421 (which expresses protein
with a hexahistidine-tag fusion that is cleavable with 3C protease to
leave a minimal four-amino-acid sequence at the N-terminus) or
AVA-MBP (which expresses protein with an N-terminal hexahisti-
dine tag in tandem with MBP that is cleavable with 3C protease) by
ligation-independent cloning(LIC;Aslanidis&DeJong,1990;Fig.1).
Brieﬂy, puriﬁed PCR product was treated with T4 polymerase in the
presence of the single nucleotide dATP, creating overhangs, and then
annealed with compatible, linearized and T4-treated AVA0421 vector
(Mehlin et al., 2006). Annealed vector and insert were transformed
into NovaBlue competent cells (Novagen, catalog No. 71011-4) and
plated on LB agar (BD Difco LB Agar Miller; BD, catalog No.
244520) with 50 mgm l
 1 each of ampicillin (Anatrace, catalog
No. A1000) and carbenicillin (Duchefa Biochemie, catalog No.
C0109.0025) to select for cells carrying the expression plasmid. The
presence of the insert was veriﬁed by colony PCR (using the above
conditions but the colony was resuspended in water and used as
template instead of puriﬁed DNA). Plasmid DNA was puriﬁed
(QIAprep Turbo mini-prep kit; Qiagen, catalog No. 27191) from 1 ml
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Figure 1
Comparison of AVA vector and AVA-MBP vector.
Figure 2
Distribution of protein solubility by species, grouped by prokaryotic and eukaryotic
kingdoms.overnight cultures and then transformed into the expression host
Rosetta Oxford [BL21 Star(DE3)-R3-pRARE2] (Choi et al., 2011).
For protein puriﬁcation, 2 l cultures of the clone were grown in
a LEX bioreactor (Harbinger) at 293 K in auto-induction medium
(Studier, 2005). After 72 h of growth, the culture was pelleted
(Sorvall RC 12BP ﬁtted with an H-12000 rotor; spun for 20 min at
4300 rev min
 1) and the cell paste was harvested and ﬂash-frozen in
liquid nitrogen. To prepare protein samples, the cell paste was solu-
bilized in 200 ml lysis buffer (25 mM HEPES, 500 mM NaCl, 5%
glycerol, 30 mM imidazole, 0.5% CHAPS, 10 mM MgCl2,1 m M
TCEP, 25 mgm l
 1 AEBSF pH 7.0) with 0.01 g lysozyme and soni-
cated for 30 min (100 W, cycles of 15 s pulse-on and 15 s pulse-off;
Virtis, catalog No. 408912). After sonication, the samples were
treated with benzonase (500 U) and then centrifuged for 1 h
(14 000 rev min
 1 in a Sorvall SLA-1500 rotor) to clarify the cell
debris. The protein was puriﬁed by immobilized metal ion-afﬁnity
chromatography on pre-equilibrated (25 mM HEPES pH 7.0,
500 mM NaCl, 5% glycerol, 30 mM imidazole, 1 mM TCEP and
0.025% azide) 5 ml Ni Sepharose columns (HisTrap FF; GE
Healthcare, catalog No. 17-5255-01) using an A ¨TKAexplorer. After
thorough washing, the bound protein was eluted from the nickel
column by addition of elution buffer (25 mM HEPES pH 7.0, 500 mM
NaCl, 5% glycerol, 1 mM TCEP, 250 mM imidazole and 0.025%
azide). Fractions from nickel-afﬁnity chromatography were analyzed
for protein content and pooled. The N-terminal 6 His tag was
removed by treatment with His-MBP-3C protease overnight at 277 K
in 3C buffer (25 mM HEPES pH 7.0, 200 mM NaCl, 5% glycerol,
1m M TCEP, 0.025% azide). Cleaved protein samples were passed
over Ni resin beads (Ni Sepharose 6 Fast Flow; GE Healthcare,
catalog No. 17-5318-02) to remove noncleaved protein, the cleaved
6 His tag, 3C protease and contaminants that bind to nickel. Clar-
iﬁed cleaved protein was then further puriﬁed by size-exclusion
chromatography (SEC; HiLoad 26/60 Superdex 75; GE Healthcare,
catalog No. 17-1071-01) using an A ¨TKAprime to collect fractions in
SEC buffer (25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol,
2m M DTT, 0.025% azide). SEC fractions were analyzed by SDS–
PAGE. The highest intensity SEC fractions were pooled and
concentrated (Amicon Ultra-15 concentrator with a molecular-
weight cutoff of 3000 Da; Fisher, catalog No. UFC901096). Protein
samples were aliquoted in 100 ml volumes, ﬂash-frozen in liquid
nitrogen and stored at 193 K.
3. Results and discussion
As part of the SSGCID structural genomics pipeline, we routinely
analyze by SDS–PAGE both the total and soluble fractions of small-
scale cultures in 96-well sets (see Choi et al., 2011) in order to identify
tractable targets for puriﬁcation. These high-throughput screens are
analyzed to identify insoluble or non-expressing constructs and, in
most cases, to remove them from the pipeline. However, the present
study further pursued these cases of suboptimal expression in order
to directly compare His-tag-fusion expression with MBP-fusion
expression. Our speciﬁc goal was to quantity the frequency with
which adding MBP to a protein increased expression and solubility
sufﬁciently to allow puriﬁcation. We modiﬁed our His-tag E. coli
expression vector to include an MBP tag between the hexahistidine
residues and the 3C cleavage recognition site (allowing cleavage of
the N-terminal tag during puriﬁcation) four amino acids upstream
of the methionine start signal of the target protein, while maintaining
the same insertion sequence (Fig. 1). This design strategy allowed us
to efﬁciently employ the same PCR-ampliﬁed T4 polymerase-treated
product for LIC insertion into either vector without requiring further
modiﬁcation.
From the entire set of constructs screened for the SSGCID project
in our standard expression vector with the minimal His tag, we
identiﬁed 497 unique clones that had neither total nor soluble protein
expression. From this group of nearly 500 targets, we veriﬁed by
sequencing that 295 of the constructs contained the expected gene
sequence, eliminating the possibility of an empty vector as the reason
for the lack of protein expression and verifying correct PCR ampli-
ﬁcation.95ofthesegeneswereselectedforfurtherstudybasedonour
desire to cover a wide range of protein functions from both
prokaryotic and eukaryotic organisms (see Supplementary Material
1
for a complete list of proteins).
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Figure 3
SDS–PAGE and SEC chromatogram of an exemplary rescued target which was easily puriﬁed. Even after cleavage and removal of the His-MBP tag, the target protein
remained soluble and expressed at the expected size. (a) SDS–PAGE of samples from initial IMAC puriﬁcation and subsequent 3C cleavage of the His-MBP tag.P represents
pure sample after the ﬁrst IMAC step; the observed molecular weight corresponds to the expected size of the recombinant protein expressed with fused MBP. After cleavage
with 3C protease, His-MBP is retained on subsequent IMAC (E), while ﬂowthrough (FT) and wash (W) samples contained protein that passes over the nickel column
unbound. Unbound recombinant protein was pooled and subjected to SEC. (b) Chromatogram of SEC indicating fractions and sieving properties of smaller molecular-
weight protein (without MBP tag). (c) SDS–PAGE of SEC fractions showing the purity of the ﬁnal preparation. M, molecular-weight marker; T, sample from total lysate; S,
sample from soluble fraction after centrifugation. The protein expressed and puriﬁed was an uncharacterized protein from Coccidioides immitis.
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: EN5465).Of the 95 targets selected for this study, 94 were successfully cloned
into the expression host and screened for solubility. The vast majority
of the targets (72%) expressed some level of protein of the expected
size (the combined size of the target protein and MBP) as visualized
by SDS–PAGE. 58 targets (62%) additionally had protein of the
expected size in the soluble fraction. The majority (37) of these had
detectable but low soluble expression (band easily visible on the gel),
11 samples had medium solubility (representing roughly 20–40% of
soluble protein) and ten had high soluble expression levels (repre-
senting  40% of the soluble protein). Of the 36 remaining targets, 23
expressed a protein band which corresponded to the expected size
of MBP alone, indicating that in these samples MBP was solubly
expressed but not the fusion partner. Rescue rates were fairly similar
among targets from prokaryotic and eukaryotic sources (Fig. 2).
To date, puriﬁcations have been attempted on 21 of the 58 solubly
expressing proteins. 15 of these puriﬁcations yielded >1 mg puriﬁed
protein; in 12 cases the abundance and purity of the target sample
were considered to be adequate for crystallization trials (Fig. 3) and
in one case crystals suitable for X-ray diffraction were obtained. This
low success rate (obtaining crystals from only one of 21 attempted
puriﬁcations) reﬂects the fact that the target proteins were usually of
poor solubility after the MBP tag had been removed. Even in the
12 best puriﬁcations mentioned above yields of the MBP-free target
protein were low (often 1–10 mg) and they were sometimes con-
taminated with signiﬁcant amounts of still uncleaved protein (Fig. 4).
Insolubility may be an intrinsic property of a particular protein
or may be a consequence of inadequate folding properties of the
expression host. Our observations are consistent with MBP being a
transiently stabilizing protein, with partner proteins falling out of
solution once MBP is removed. One model is that highly soluble
MBP acts as a chaperone by sequestering the aggregation-prone
passenger protein, allowing native conformational folding of the
nascent protein but in a weak reversible manner (Kapust & Waugh,
1999). Recent studies have made available new fusion constructs with
mutations to MBP to decrease the surface entropy and increase the
rigidity of the polypeptide sequence linking MBP to the recombinant
protein (Moon et al., 2010). These modiﬁcations have allowed direct
structure solution by X-ray crystallography and molecular replace-
ment without necessitating the removal of the MBP tag (Smyth et al.,
2003; Moon et al., 2010). Although further advancements need to be
made for this to be viable as a high-throughput rescue strategy, this
approach shows promise for those recombinant protein products that
could not be separated from the MBP tag by 3C cleavage. Other
solubility-enhancing tags, such as SUMO expression systems, are a
potential alternative for rescue of insoluble or non-expressing
recombinant constructs (Yunus & Lima, 2009).
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Figure 4
Example of more typical protein-puriﬁcation products. Large quantities of fused protein running at the molecular weight of target protein and MBP combined are visible in
the total (T) and soluble (S) fractions. (a) After cleavage, two forms of the protein remain visible: a band corresponding to the size of MBP and a band corresponding to the
size of MBP plus the target protein; very little to no target protein remains in solution. A chromatogram (b) and SDS–PAGE (c) of SEC fractions from uncleaved sample
indicate a heterogenous solution of either the recombinant protein expressed with MBP (higher molecular-weight band) or MBP alone (lower molecular-weight band). M,
molecular-weight marker; T, total lysate; S, soluble fraction; FT, ﬂowthrough from IMAC after 3C cleavage; W, wash after 3C cleavage; E, eluate with 250 mM imidazole from
IMAC after 3C cleavage. The protein expressed and puriﬁed was Brucella abortus blue (type 1) copper protein.